Melanoma antigen preferentially expressed in tumors (425-433)

Melanoma antigen preferentially expressed in tumors

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.

CAT No: ta-389

Synonyms/Alias:Melanoma antigen preferentially expressed in tumors (425-433)

Custom Peptide Synthesis
cGMP Peptide
  • Registration of APIs
  • CMC information required for an IND
  • IND and NDA support
  • Drug master files (DMF) filing
Sequence
SLLQHLIGL
Areas of Interest
Antigen-presenting Cells; Cancer Research
Source#
Homo sapiens (human)
Epitope
425-433
Restricting HLA
HLA-A2
References
Kessler; J Exp Med 2001

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Featured Services
cGMP Peptide ServicePeptide Analysis ServicesPeptide Nucleic Acids SynthesisCustom Conjugation ServicePeptide CDMOEpitope Mapping ServicesPeptide Synthesis ServicesPeptide Modification Services
Hot Products
About us

Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.

From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.

Our Customers